Kornimate/medical-research-clean huggingface dataset:
anesthetic efficacy of gow-gates versus conventional inferior alveolar nerve block techniques

Conditions: Anesthesia; Reaction; Pain

Summary: the purpose of this study is to determine whether gow gates block injection is more effective than conventional alveolar nerve block in anesthetising mandibular molars with acute pulpitis.

pain management and adequate anesthesia are of critical importance for the endodontist. traditionally, mandibular teeth are anesthetized via inferior alveolar nerve block (ian). however, this technique provides a marginal success rate of 19-56% in patients with irreversible pulpitis.gow gates technique introduced in 1973 for anesthetizing of mandibular molars with more accuracy, success and safety.

Eligibility criteria:
inclusion criteria: * mandibular molars with acute irreversible pulpitis exclusion criteria: * unhealthy patients * patients who had taken pain killer less than 4 hours before appointment
oxytocin in spectrum autism disorders

Conditions: Autistic Disorder

Summary: observe effects of oxytocin on individuals with autism spectrum disorder

to observe the effects of oxytocin on individuals with autism spectrum disorder according to gender, in facial recognition and eye tracking tests. the investigators will apply the nepsy and eye tracking tests before and 45 minutes after the puff with oxytocin or placebo at the dose of 0.4 iu / kg / dose maximum of 24 iu. the next week the volunteer will return and will do the same procedure because whoever took the placebo would take oxytocin and vice versa. is a randomized, double-blind, placebo-controlled clinical trial.

Eligibility criteria:
inclusion criteria:diagnosis of asd by dsmv * cars\> 30 * age between 3 and 16 years * stable (3 months with medication maintained or without medication) exclusion criteria:- pregnant women, infants and * participation in another research project of pharmacological or behavioral intervention in progress * use of pituitary hormones, cortisol, androgens and estrogens. * heart problems: recent ami, heart failure. * respiratory problems: pneumonia, respiratory failure, decompensated asthma, acute bronchitis.
effect of cocoa flavanols on vascular function

Conditions: Coronary Artery Disease

Summary: endothelial dysfunction is associated with a higher incidence of adverse cardiovascular events in patients with coronary artery disease (cad). cad patients also show impaired function and number of endothelial progenitor cells (epcs, adult stem cells) which circulate in adult blood and contribute to endothelial repair. clinical studies suggest that endothelial function can be improved in cad patients by consumption of flavanol-rich cocoa. yet, the mechanism is not known. it is also not known whether flavanol-rich cocoa provides an additive, positive effect in patients who are already receiving the maximal recommended therapies for risk factor modification. therefore, the researchers propose to perform an investigator-initiated, randomized controlled cross-over study administering flavanol-rich cocoa or a placebo for two months in cad patients on optimal medical therapy. an improvement of endothelial function as measured by flow-mediated dilation (fmd) will be the primary endpoint of this study. the researchers propose to also measure determinants of fmd such as microvascular response, inflammatory markers, metabolites of nitric oxide, as well as the number and function of epcs in the blood. importantly, detailed food questionnaires and plasma flavanols/metabolites will help to further support a causal link between flavanol-intake and improved vascular function.


Eligibility criteria:
inclusion criteria: * cad patients over 18 years of age * contact university for more details. exclusion criteria: * contact university for more details.

Keywords: cad patients on optimal treatment
evolution of the lymphocyte phenotype in patients with infection in intensive care unit

Conditions: Patients Undergoing Esophagectomy; Patients with Severe Polytrauma; Patients with Severe Neurological Lesion; Patients with Abdominal Infection

Summary: patients admitted for polytrauma, severe neurological injury, post-operative monitoring or sepsis/septic shock present with significant inflammation, leading to immunoparalysis, which is responsible for infection, particularly prolonged infection. a study of their lymphocyte phenotype over time could help explore the phenomenon of immunoparalysis.


Eligibility criteria:
inclusion criteria: * postoperative esophagectomy surveillance within the last 24 hours. * patients with intra-abdominal infection * neurological patients with intubation planned for more than 24 hours (subarachnoid hemorrhage with coma, severe head trauma, ischemic or hemorrhagic stroke with coma). * polytrauma with intubation planned for more than 24 hours * patient aged 18 and over * patient with social security coverage non-inclusion criteria : * hereditary immune deficiency hiv-aids * malignant hemopathies * immunosuppressive treatment other than corticosteroid therapy or chemotherapy * patient under legal protection * pregnant or breast-feeding women
extended evaluation of prochymal® adult human stem cells for treatment-resistant moderate-to-severe crohn's disease

Conditions: Crohn's Disease

Summary: protocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in crohn's disease activity index (cdai) of at least 100 points) in protocol 603. protocol 610 is evaluating the length of initial effect of prochymal® adult human mesenchymal stem cells and the ability of these cells to successfully re-induce clinical benefit.

a significant number of individuals with crohn's disease do not find relief with existing steroidal, immunosuppressive, or biologic therapies, and are forced to seek surgery or other drastic measures for treatment. prochymal® adult human stem cells are manufactured from healthy, volunteer donors, extensively tested, and are stored to be available as needed. human and animal studies have shown that the cells do not require any donor-recipient matching. the cells may have both immunosuppressive and healing benefits in crohn's disease. the cells naturally migrate specifically to sites of inflammation, so their effects are believed to be local and self-limiting rather than systemic. protocol 610 is an extension study offered only to those subjects who successfully achieved clinical benefit (reduction of cdai of at least 100 points) in protocol 603.

Eligibility criteria:
inclusion criteria: * participation in osiris protocol 603, with drop of at least 100 points in cdai at day 28 exclusion criteria: * substance abuse * failure to receive full dose of all interventions in protocol 603
ethnicity and onset of cardiovascular disease: a caliber study

Conditions: Abdominal Aortic Aneurysm; Coronary Heart Disease; Sudden Cardiac Death; Intracerebral Haemorrhage; Heart Failure; Ischemic Stroke; Myocardial Infarction; Stroke; Peripheral Arterial Disease; Stable Angina Pectoris; Subarachnoid Haemorrhage; Transient Ischemic Attack; Unstable Angina; Cardiac Arrest

Summary: specific cardiovascular diseases, such as stroke and heart attack, have been shown to vary by ethnic group. however, less is known about differences between ethnic groups and a wider range of cardiovascular diseases. this study will examine differences between ethnic groups (white, black, south asian and mixed/other) and first lifetime presentation of twelve different cardiovascular diseases. this information may help to predict the onset of cardiovascular diseases and inform disease prevention strategies. the hypothesis is that different ethnic groups have differing associations with the range of cardiovascular diseases studied.

there is evidence from epidemiological studies that different ethnic groups are associated with increased incidence of specific cardiovascular diseases. however, the majority of existing studies have examined associations with one or two acute conditions such as stroke or coronary heart disease or focused on a particular ethnic group. the aim of this study is to examine the differing associations between four ethnic groups and the initial lifetime presentation of a broad range of cardiovascular diseases, including chronic presentations such as stable angina. the hypothesis is that there will be heterogeneity of associations between the different ethnic groups and the full range of cardiovascular diseases studied. the study will use data from the caliber data set of clinically collected electronic health record data from england. this study is part of the caliber (cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the national institute for health research (nihr) and wellcome trust. the central theme of the caliber research is linkage of the myocardial ischaemia national audit project (minap) with primary care (clinical practice research datalink - cprd) and other resources. the overarching aim of caliber is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. caliber has received both ethics approval (ref 09/h0810/16) and ecc approval (ref ecc 2-06(b)/2009 caliber data set).

Eligibility criteria:
inclusion criteria: * patients aged 30 and over * registered with a participating general practice during the study period * minimum one year of records prior to study entry meeting cprd data quality exclusion criteria: * patients without a record of ethnic group * patients without record of gender * patients with prior atherosclerotic disease, as recorded in primary care or hospitalisation data * pregnant women in the 6 months before the eligibility date

Keywords: ethnic group cardiovascular disease atherosclerosis
evaluation of blood glucose monitoring systems with blood samples from neonates

Conditions: Diabetes

Summary: the purpose of this study was to evaluate the performance of three bayer blood glucose monitoring systems (bgms) with neonatal blood. blood samples used in this study were 'left-over samples'. the blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. all meter blood glucose (bg) results were compared with capillary plasma results obtained with a reference laboratory glucose method (cobas® 6000 instrument).


Eligibility criteria:
inclusion criteria: * routine blood samples (heelstick) collected from neonates (less than 30 days of age). * a portion of the samples (approximately 10%) will be from subjects \<24 hours old. * a portion of the samples (at least 10%) will be from subjects in the nicu. * sample blood volume must be sufficient to complete investigational testing in addition to prescribed testing. exclusion criteria: * samples from babies \>=30 days of age
non-inferiority study of gsk biologicals' influenza vaccine gsk576389a using different formulations

Conditions: Influenza

Summary: the purpose of this study is to show the non-inferiority of different formulations of glaxosmithkline biologicials' influenza vaccine.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * a male or female 65 years of age or older at the time of vaccination. * written informed consent obtained from the subject. * free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study. exclusion criteria: * suspected (based on clinical symptoms) or confirmed (based on laboratory results) influenza infection within the last 6 months. * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. planned administration of a vaccine not foreseen by the study protocol up to 21 days after vaccination. * planned administration of an influenza vaccine other than the study vaccines during the entire study period. * previous vaccination against influenza with any seasonal vaccine since july 2007. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * history of hypersensitivity to a previous dose of influenza vaccine. * history of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg and chicken protein. * acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests. * acute disease at the time of enrolment. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * any medical conditions in which im injections are contraindicated

Keywords: influenza
probiotic administartion to mothers of preterm infants to prevent necrotizing enterocolitis and sepsis

Conditions: Necrotizing Enterocolitis; Sepsis

Summary: we hypothesize that supplementing maternal diet with probiotics will decrease the incidence of feeding intolerance, necrotizing enterocolitis and sepsis in preterm infants fed breastmilk.

oral probiotics have previously been shown to prevent necrotizing enterocolitis in preterm infants. a few reports of sepsis by a probiotic bacteria have impeded implementation of oral probiotic supplementation in most nicus. considering the proven immunomodulatory effect of maternal probiotics on breastfed infants of atopic mothers, we would like to explore the indirect effects of maternal probiotics on preterm infants

Eligibility criteria:
inclusion criteria: * mothers of preterm infants * pumping breast milk exclusion criteria: * neonatal congenital anomalies

Keywords: probiotic preterm lactation breast feeding necrotizing enterocolitis sepsis bacterial cultures lactating mother breast feeding of at least 50% of enteric feeding volume infant, very low birth weight
relieve the patient's thirst, refresh the mouth first (icu-mic)

Conditions: Hypernatremia; Dehydration

Summary: thirst is considered as one of the most distressing symptoms experienced by patients hospitalized in the intensive care unit (icu). whereas pain is a permanent concern for all caregivers, thirst is often ignored and its complications are poorly known. mechanisms involved in thirst regulation are numerous and complex. to date, care of thirst is still non optimal. critically ill patients are usually rehydrated intravenously or using a naso-gastric tube, thus shunting the mouth as a therapeutic target to relieve the patient's thirst. water, cold and mint applied in mouth were studied separately and were shown to decrease thirst significantly on animal models and healthy humans. therefore, the hypothesis of this study is that application of small mint ice cubes in mouth of very dehydrated icu patients should allow decreasing quickly and significantly thirst for these patients, before the correction of their biological parameters, like natremia and osmolarity.


Eligibility criteria:
inclusion criteria: * hypernatremia upper than 150mmol/l or hypernatremia upper than 145mmol/l associated with water deficiency upper than 3l * estimated hospitalization duration in icu upper than 24h exclusion criteria: * contraindication for ice cubes application in mouth * known mint allergy * incapability to understand study outcome and to answer basic questions * pregnancy * dying person

Keywords: thirst mouth critical care water deprivation
safety and efficacy of prulifloxacin versus placebo in traveler's diarrhea

Conditions: Acute Gastroenteritis in Adult Travelers

Summary: the objective of this pivotal phase iii study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.

this double-blind trial will compare the safety and efficacy of prulifloxacin versus placebo in adult travelers with acute gastroenteritis characterized by diarrhea with one or more of the following signs or symptoms: nausea, vomiting, abdominal pain or cramping, fecal urgency, moderate to severe gas-related symptoms, or tenesmus of ≤72 hours duration.

Eligibility criteria:
inclusion criteria: * diagnosis of acute bacterial gastroenteritis; * traveler from industrialized country; * capable of giving informed consent exclusion criteria: * fever (\>100.3 degrees); * pregnant or breast feeding or not using adequate birth control; * known or suspected (co-)infection with non-bacterial pathogen; * symptoms of gastroenteritis of \>72 hours; * bloody diarrhea; * concomitant antibacterial with activity against enteric bacterial pathogens; * history of ibd; * unable/unwilling to comply with study protocol; * \> 2 doses of anti-diarrheal medication within 24 hours; * antimicrobial treatment within 30 days

Keywords: gastroenteritis
eating phenotypes for childhood obesity in the context of familial obesity risk

Conditions: Obesity

Summary: using an integrated approach, this study examines multiple eating traits concurrently under states of hunger and satiety. it examines the impact of short-term appetite and intake regulation on longer-term energy intake control and weight development in a cohort of ethnically diverse normal-weight and obese boys and girls with different familial predispositions to obesity.


Eligibility criteria:
inclusion criteria: * 7-9 years of age * normal-weight or overweight/obese who are at low risk or high risk for obesity based on maternal bmi * like most foods served during the study * be regular breakfast eaters exclusion criteria: * have serious medical conditions known to affect food intake or body weight * have any developmental, medical, or psychiatric conditions that might impact study compliance * have a learning disability or poor reading ability/comprehension * have visual or auditory impairment * are taking medications associated with developmental, medical, or psychiatric disorders or medications known to affect appetite, food intake or body weight * are underweight * have food allergies related to the foods served in the study or are lactose intolerant * do not regularly eat breakfast * do not like or cannot eat foods served during experimental meal or are unable to finish compulsory preload * mothers who are pregnant
development and testing of an electronic behavioral health record specific to the wraparound care coordination process

Conditions: Serious Emotional Disturbance of Youth

Summary: the purpose of this phase ii small business technology transfer (sttr) project is to complete development and evaluate usability and effectiveness of the wraparound team monitoring system (wrap-tms), a web-based, electronic behavioral health information system (ebhis) for the most widely implemented care coordination model in children's behavioral health, the wraparound process. though wraparound is now considered "evidence-based," implementation in the real world often fails to conform to standards of fidelity and/or use objective data to guide management, supervision, and clinical decision making. availability of such a system will support efficiency, implementation quality and fidelity, and outcomes for youths enrolled in wraparound. wrap-tms features functionality for data entry, management, and basic reporting for the full array of data and information elements needed to manage an integrated care coordination initiative for youths with serious emotional and behavioral disorder (sebd). in light of our success in phase i, subsequent partnerships with federal agencies, and inquiries of interest from several states and over 20 provider and managed care organizations, in this phase ii sttr the investigators will complete development of wrap-tms, followed by a randomized controlled effectiveness study comparing n=25 wraparound facilitators who use wrap-tms serving n=100 families to 25 non-user facilitators serving 100 families on practitioner, implementation, and youth/family outcomes. the evaluation will test two primary hypotheses: 1. compared to facilitators in the control group, wraparound facilitators trained to use wrap-tms will demonstrate (a) greater use of data and feedback in service delivery; (b) greater fidelity to the wraparound process; (c) higher self-reported teamwork, working alliance, and satisfaction with the intervention; and (d) more positive attitudes toward standardized assessment. 2. compared to the control group, parents of youths receiving services from facilitators trained to use tms will report (a) greater goal clarity, (b) more data collection and use (c) greater satisfaction with services and progress, (d) better fidelity to wraparound, (e) more effective team functioning, (f) greater treatment alliance, and (f) better youth outcomes including greater progress and improved symptoms and functioning.


Eligibility criteria:
inclusion criteria: * parent or legal guardian of a youth aged 6-17 with sebd (serious emotional and behavioral disorder): at least one mh (mental health) diagnosis that results in long-term (\>6 mos) impairment in home, school and/or community functioning). exclusion criteria: * non english speaking parents * foster parents

Keywords: patient care team care management electronic health records
ventilation heterogeneity prior to lung resection

Conditions: Lung Cancer

Summary: this is a single centre prospective six-week observational study to understand the prevalence and clinical relevance of abnormal ventilation of the lung (assessed by technegas ventilation single photon emission computed tomography (v spect) and hyperpolarized 129xe magnetic resonance imaging (mri)), in the presence or absence of airway inflammation (assessed by sputum cell counts), in lung cancer patients prior to lung resection surgery.


Eligibility criteria:
inclusion criteria: * undergoing lung resection for lung cancer at st. joseph's healthcare (hamilton, ontario) in accordance with british thoracic society guidelines. * males and females ≥ 18 years of age. * able and willing to provide written informed consent. * able and willing to comply with the study protocol. exclusion criteria: * previous lung resection surgery. * previous chest radiation. * patient has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples. * in the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the mri, such as severe claustrophobia. * pregnancy.

Keywords: lung cancer lung resection ventilation heterogeneity technegas v spect hyperpolarized 129xe mri airway inflammation